Jade Biosciences, Inc. (JBIO) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $6.00K; Additional Paid in CapitalUSD $711.09M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-660.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $5.00K; Additional Paid in CapitalUSD $511.55M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-342.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $5.00K; Additional Paid in CapitalUSD $506.77M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $129.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $2.00K; Common Stock, Value, IssuedUSD $3.00K; Additional Paid in CapitalUSD $321.77M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $29.00K.
Jade Biosciences, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $6.00K | $711.09M | $-660.00K | $-270.52M | $439.92M | 3 month · $6.50M | (m) |
| 2026-03-31 | (m) | $5.00K | $511.55M | $-342.00K | $-214.76M | $296.46M | 3 month · $4.74M | (m) |
| 2025-12-31 | (m) | $5.00K | $506.77M | $129.00K | $-174.39M | $332.52M | 12 month · $9.94M | 12 month · $11.14M |
| 2025-09-30 | $2.00K | $3.00K | $321.77M | $29.00K | $-142.46M | $179.35M | 3 month · $2.91M | (m) |
| 2025-06-30 | $2.00K | $3.00K | $318.86M | $-24.00K | $-117.28M | $201.56M | 3 month · $2.37M | (m) |
| 2025-03-31 | (m) | $3.00K | $310.56M | $50.00K | $-235.57M | $-83.51M | 3 month · $1.46M | (m) |
| 2024-12-31 | (m) | $1.00K | $179.00K | $0.00 | $-46.98M | $-46.80M | 6 month · $179.00K 12 month · $11.31M | (m) |
| 2024-09-30 | (m) | $3.00K | $307.89M | $224.00K | $-227.62M | $-16.86M | 3 month · $3.00K | (m) |
| 2024-06-30 | (m) | $3.00K | $305.86M | $-83.00K | $-211.38M | $-589.00K | 3 month · $3.87M | (m) |
| 2024-06-17 | (m) | (m) | (m) | (m) | (m) | $1.00K | (m) | (m) |
| 2024-03-31 | (m) | $3.00K | $277.54M | $-33.00K | $-186.61M | $90.90M | 3 month · $4.20M | (m) |
| 2023-12-31 | (m) | $3.00K | $272.64M | $237.00K | $-163.42M | $109.46M | 12 month · $11.91M | (m) |
| 2023-09-30 | (m) | $3.00K | $268.93M | $-195.00K | $-143.01M | $125.72M | 3 month · $3.24M | (m) |
| 2023-06-30 | (m) | $3.00K | $265.59M | $-223.00K | $-123.45M | $141.93M | 3 month · $3.03M | (m) |
| 2023-03-31 | (m) | $2.00K | $217.72M | $-201.00K | $-104.42M | $113.09M | 3 month · $2.38M | (m) |
| 2022-12-31 | (m) | $2.00K | $215.11M | $-466.00K | $-87.90M | $126.74M | 12 month · $5.48M | (m) |
| 2022-09-30 | (m) | $2.00K | $212.79M | $-771.00K | $-72.88M | $139.14M | 3 month · $1.50M | (m) |
| 2022-06-30 | (m) | $2.00K | $211.13M | $-785.00K | $-59.29M | $151.05M | 3 month · $1.22M | (m) |
| 2022-03-31 | (m) | $2.00K | $209.89M | $-644.00K | $-47.30M | $161.95M | 3 month · $1.02M | (m) |
| 2021-12-31 | (m) | $2.00K | $208.87M | $-59.00K | $-36.39M | $172.42M | 12 month · $2.04M | (m) |
| 2021-09-30 | (m) | $2.00K | $208.01M | (m) | $-28.17M | $179.85M | 3 month · $845.00K | (m) |
| 2021-06-30 | (m) | (m) | $407.00K | (m) | $-21.98M | $-21.58M | 3 month · $321.00K | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | $-16.11M | 3 month · $23.00K | (m) |
| 2020-12-31 | (m) | (m) | $63.00K | (m) | $-13.41M | $-13.34M | 12 month · $58.00K | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | $-9.70M | 3 month · $21.00K | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | $-7.27M | 3 month · $6.00K | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | $-5.07M | 3 month · $7.00K | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | $-3.64M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |